Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06869785 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
A Phase 3 study of Relapsing Multiple Sclerosis (RMS), sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
- 20
- Study locations
NCT06869785 is a Phase 3 study of Relapsing Multiple Sclerosis (RMS) that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 196 participants, below the 731-participant average among 3 other Relapsing Multiple Sclerosis (RMS) trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06869785, a Phase 3 study of Relapsing Multiple Sclerosis (RMS), is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
Conditions Studied
Interventions
- BIOLOGICAL Ofatumumab approved dose
- BIOLOGICAL Ofatumumab new dose
Study Locations (20)
Florida
- Neurology of Central FL Res Ctr - Altamonte Springs
- Neurology Offices Of South Florida - Boca Raton
- First Choice Neurology - Boca Raton
- University of Florida - Gainesville
- Memorial Healthcare System - Hollywood
- Neurology Associates PA - Maitland
- UM Department Of Neurology - Miami
- Elite Clinical Research - Miami
California
- The Research and Education Inst. of Alta Bates Summit Med. Grp - Berkeley
- Fullerton Neuro and Headache Ctr - Fullerton
- University of California Irvine - Irvine
- CenExcel Clinical Research - Los Alamitos
- Velocity Clinical Trials - Los Angeles
- Regina Berkovich MD PhD Inc - West Hollywood
Arizona
- Xenoscience Inc - Phoenix
- Ctr for Neurology and Spine - Phoenix
- Phoenix Neurological Associates - Phoenix
Alabama
- Alabama Neurology Associates PC - Birmingham
Colorado
- CU Anschutz Med Campus - Aurora
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2030-03-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06869785
The ClinicalTrials.gov registry entry for NCT06869785 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 731-participant average among 3 other Relapsing Multiple Sclerosis (RMS) trials with a reported enrollment target (73% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis (RMS) appearing as the primary indexed condition, and to 2 interventions - of which Ofatumumab approved dose is the first listed.
NCT06869785 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06869785 about?
NCT06869785 is a clinical study titled "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab". This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
What is the current status of trial NCT06869785?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2025-03-13. Estimated completion is 2030-03-23.
What conditions does trial NCT06869785 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis (RMS).
What interventions are being tested in trial NCT06869785?
The interventions under investigation include: Ofatumumab approved dose (BIOLOGICAL), Ofatumumab new dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT06869785?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06869785 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis (RMS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
COMPLETED · Phase 3
-
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.